NEW YORK&8211;BUSINESS WIRE&8211;New data show that switching patients with Crohns disease CD to INFLECTRA infliximab CTP13 from REMICADE infliximab led to comparable efficacy safety and tolerability to treatment with REMICADE over a 24 week period...
↧